Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Placenta-derived mesenchymal stem cell secretome for graft-versus-host disease
IRCT20201108049311N7Phase 3Completed
- Sponsor
- Tabriz University of Medical Sciences
- Start
- Aug 2023
- Modality
- Cell Therapies, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, triple-blind trial of mesenchymal stem cell secretome in graft-versus-host disease (GVHD) (2 arms), sponsored by Tabriz University of Medical Sciences. Primary endpoints: Skin rash, Liver involvement and 1 more. Started Aug 2023; status: completed.
02
Drugs
mesenchymal stem cell secretome
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on IRCT20201108049311N7.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20201108049311N7.